|Oncopeptides is working to enhance oncology therapies, by creating cytosuperiors of existing basic cytotoxic compounds. Oncopeptides lead compound, named melflufen, is a cytosuperior of the chemotherapeutic alkylator melphalan.Melflufen is currently undergoing Phase II efficacy studies in patients with relapsed and/or refractory multiple myeloma. A family of enzymes that is expressed at very high levels in cancer cells, such as multiple myeloma cells, causes melflufen and its metabolites to accumulate in the diseased cells. This results in partially targeted delivery of the chemotherapeutic compound to the cancer cells, and thereby better treatment of the disease.
NEWS: Oncopeptides Initiates Phase II Clinical Study with Melflufen in the Treatment of Multiple Myeloma Patients DOWNLOAD
NEWS: Oncopeptides Secures Venture Funding for Phase II Trial of Melflufen in Multiple Myeloma Patients DOWNLOAD
NEWS: Oncopeptides AB appoints Jakob Lindberg as CEO DOWNLOAD
EVENT: Oncopeptides AB Presents the New Anticancer Agent J1 at The American Society of Hematology (ASH) Annual Meeting in Orlando, Florida, USA.